Navigation Links
WaferGen Bio-systems and QIAGEN KK Sign Agreement for Co-Marketing in Japan
Date:2/19/2013

iling as well as single nucleotide polymorphism (SNP) genotyping.

For additional information, please see http://www.wafergen.com

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2012, QIAGEN employed approximately 4,000 people in over 35 locations worldwide. QIAGEN KK is a wholly owned subsidiary of QIAGEN NV of about 100 employees who market QIAGEN's entire product portfolio across all Japanese customer classes. Further information can be found at http://www.qiagen.com  

Forward Looking Statements

This press release contains certain "forward-looking statements."  Such statements include statements relating to the expected benefits to the Company of
'/>"/>

SOURCE WaferGen Biosystems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
2. WaferGen to Present Corporate Overview at Oppenheimer Healthcare Conference
3. WaferGen to Present Corporate Overview at 5th Annual OneMedForum San Francisco 2012
4. WaferGen Bio-systems Announces Open Format qPCR Platform and Strategic Realignment
5. WaferGen Bio-systems Awarded 1 Million Euro Grant by the Luxembourg Government to expand its European Operations
6. WaferGens MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center
7. QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
8. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
9. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
10. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
11. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 Immunovaccine Inc. ... immunotherapy company, today announced that the U.S. Food ... Fast Track designation and Phase I clinical trials ... with the mutual co-development agreement signed with Gilead ... Track designation for the DPX-Survivac. , “We have ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 FamilyFarms Group ... General Manager of State Line Farms, received the 2015 ... a producer, under the age of 35, who has ... is an honor to win the Tomorrow's Top Producer ... who won the Top Producer Award and learning from ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... --  Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, today reported 2014 full year ... objectives, and financial guidance.  Synageva,s management team will ... EST to review the financial results and provide ... call by telephone, please dial (877) 445-4603 for ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... writing a series of articles on raising capital from angel ... Placement Memorandums, or PPMs, and is co-written with Dan Ghoca. ... is necessary to use a private placement memorandum (also referred ... securities to angel investors in a private placement. Once we ...
... on the use of the country's network infrastructure may ... not capture the true essence of the total importance ... economic development. Forget the Digital Divide and view our ... Digital Desert that affects every level of the economic ...
... partner with the law firm Michael Best & Friedrich ... director of government affairs . , , Milwaukee, ... has announced $200 million in new financing for cellulosic ... with projects that may include everything from research and development ...
Cached Biology Technology:When raising capital, why use a Private Placement Memorandum? 2When raising capital, why use a Private Placement Memorandum? 3When raising capital, why use a Private Placement Memorandum? 4When raising capital, why use a Private Placement Memorandum? 5Bridging the digital divide is the wrong battle cry 2Bridging the digital divide is the wrong battle cry 3Bridging the digital divide is the wrong battle cry 4Wisconsin applicants urged to pursue DOE funding for cellulosic biomass 2
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/11/2015)... , February 11, 2015 ... research report "Access Control Market by Product (Cards and ... Residential, Military and Defense, Government, Industrial, Healthcare, Education) and ... published by MarketsandMarkets, the Access Control Market ... 2020, growing at a CAGR of 10.6% ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... study, "Socioeconomic Conditions Along the World,s Tropical Coasts: 2008," ... healthy coral reefs in 27 tropical nations and points ... decades-old recommendations as a significant barrier to coral reef ... quadrennial "Status of Coral Reefs of the World: 2008" ...
... of the bowel can have genetic causes. Researchers at ... have discovered this correlation. The causes of what is ... most common disorders of the gastrointestinal tract, are considered ... results from Heidelberg, which were published in the prestigious ...
... Michigan State University chemist could eventually lead to a ... are key to treating a number of diseases, including ... manufacture and research often are made within genetically modified ... tends to collect into what scientists call inclusion bodies. ...
Cached Biology News:First-ever socioeconomic study on coral reefs points to challenges of coastal resource management 2First-ever socioeconomic study on coral reefs points to challenges of coastal resource management 3Irritable bowel syndrome can have genetic causes 2
... tested on rat tissue extracts (liver, kidney, spleen, ... cerevisae ) extract. It was also tested with ... lines. Application: A simple and reliable method for ... the detection of the inorganic phosphate released from ...
... the leader in electroporation products and specialty ... product line for experiment optimization and large ... a breakthrough in Molecular Delivery. The days ... that typically limited the number of samples ...
... 20 System revolutionizes DNA sequencing, delivering sequence ... The Genome Sequencer 20 System includes: ... consumables for library construction, amplification, and sequencing ... novo assembly The instrument ...
... RapidVUE is a particle shape and size analyzer ... designed with the utmost simplicity in mind. It ... module and an optical bench. The system is ... easy upgrade for different applications such as dry ...
Biology Products: